Literature DB >> 20459092

Crystallization of amorphous indomethacin during dissolution: effect of processing and annealing.

Kristyn Greco1, Robin Bogner.   

Abstract

The crystallization of amorphous drugs during dissolution is a type of solution mediated phase transformation that can reduce the bioavailability enhancement one hoped to gain from the amorphous state. The goal of this study was to explore the effects of processing on the dissolution performance of amorphous indomethacin. The amorphous solids were prepared by four techniques, quench cooling the melted solid, cryogrinding γ indomethacin amorphous for 1 or 3 h and quench cooling the solid followed by 1 h of cryogrinding. Dissolution results assessed in a flow-through intrinsic dissolution apparatus reveal decreases in the dissolution rate of amorphous indomethacin during the experimental time frame indicating that a solution mediated phase transformation has occurred. The amorphous solids prepared by melt quenching and melt quenching followed by cryogrinding showed a significant dissolution rate advantage over the γ form of indomethacin. In contrast, indomethacin that was cryoground amorphous for 1 or 3 h did not show any dissolution rate advantage over the crystalline material. Transformation was confirmed by in situ Raman microscopy and polarized light microscopy with differences seen in the nature of the crystals apparent on the surface of the dissolving solid. A portion of the melt quenched amorphous sample was annealed at 25 °C and 0% relative humidity to induce partial crystallization of γ indomethacin. As crystallinity increased, the dissolution rate decreased. The transformation time of partially amorphous indomethacin was not dependent on the level of crystallinity present, indicating only a small fraction of crystalline material needs to be present to affect the kinetics of crystallization. The solution mediated phase transformation of amorphous indomethacin is affected by the processing method even though all solids were confirmed amorphous by polarized light microscopy and X-ray diffraction. Dissolution may distinguish differences in amorphous solids that other methods cannot discern.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20459092     DOI: 10.1021/mp1000197

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  14 in total

1.  Mathematical Models to Explore Potential Effects of Supersaturation and Precipitation on Oral Bioavailability of Poorly Soluble Drugs.

Authors:  Mary S Kleppe; Kelly M Forney-Stevens; Roy J Haskell; Robin H Bogner
Journal:  AAPS J       Date:  2015-04-08       Impact factor: 4.009

2.  Solid-State NMR Investigation of Drug-Excipient Interactions and Phase Behavior in Indomethacin-Eudragit E Amorphous Solid Dispersions.

Authors:  Joseph W Lubach; Jonathan Hau
Journal:  Pharm Res       Date:  2018-02-20       Impact factor: 4.200

3.  Multicomponent chemical imaging of pharmaceutical solid dosage forms with broadband CARS microscopy.

Authors:  Christopher M Hartshorn; Young Jong Lee; Charles H Camp; Zhen Liu; John Heddleston; Nicole Canfield; Timothy A Rhodes; Angela R Hight Walker; Patrick J Marsac; Marcus T Cicerone
Journal:  Anal Chem       Date:  2013-08-20       Impact factor: 6.986

4.  Solubility advantage of amorphous pharmaceuticals: II. Application of quantitative thermodynamic relationships for prediction of solubility enhancement in structurally diverse insoluble pharmaceuticals.

Authors:  Sharad B Murdande; Michael J Pikal; Ravi M Shanker; Robin H Bogner
Journal:  Pharm Res       Date:  2010-09-22       Impact factor: 4.200

Review 5.  Current and potential applications of simultaneous DSC-FTIR microspectroscopy for pharmaceutical analysis.

Authors:  Shan-Yang Lin
Journal:  J Food Drug Anal       Date:  2021-06-15       Impact factor: 6.157

6.  Amorphous solid dispersions of sulfonamide/Soluplus® and sulfonamide/PVP prepared by ball milling.

Authors:  Vincent Caron; Yun Hu; Lidia Tajber; Andrea Erxleben; Owen I Corrigan; Patrick McArdle; Anne Marie Healy
Journal:  AAPS PharmSciTech       Date:  2013-02-07       Impact factor: 3.246

7.  Polydimethylsiloxane-indomethacin blends and nanoparticles.

Authors:  Carmen Racles
Journal:  AAPS PharmSciTech       Date:  2013-06-13       Impact factor: 3.246

8.  Enhancement of the physical stability of amorphous indomethacin by mixing it with octaacetylmaltose. inter and intra molecular studies.

Authors:  E Kaminska; K Adrjanowicz; D Zakowiecki; B Milanowski; M Tarnacka; L Hawelek; M Dulski; J Pilch; W Smolka; I Kaczmarczyk-Sedlak; K Kaminski
Journal:  Pharm Res       Date:  2014-05-15       Impact factor: 4.200

9.  Image-based dissolution analysis for tracking the surface stability of amorphous powders.

Authors:  Jernej Štukelj; Mikael Agopov; Jouko Yliruusi; Clare J Strachan; Sami Svanbäck
Journal:  ADMET DMPK       Date:  2020-07-13

10.  Low- versus Mid-frequency Raman Spectroscopy for in Situ Analysis of Crystallization in Slurries.

Authors:  Jaana Koskela; Joshua J Sutton; Tiina Lipiäinen; Keith C Gordon; Clare J Strachan; Sara J Fraser-Miller
Journal:  Mol Pharm       Date:  2022-05-03       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.